Replies to post #198353 on Biotech Values

[DewDiligence]

EGRX cash position is starting to swell… Currently they have around $100M on hand… another $30M coming for J-Code approval.

Don’t forget the $15M milestone for the Bendeka launch in early 2016 (which will come before the J-Code milestone).

What to do with all this cash?

It’s a nice problem to have.